Press Release
Foundation Fifteen Launches Lifesaving Mental Health Campaign in Noel, MO to Support At-Risk Youth in Memory of Landen Russell Cates
New initiative aims to provide crucial mental health resources and support for vulnerable teens, honoring the memory of Landen Russell Cates
Noel, Missouri, 19th August 2025, ZEX PR WIRE, Foundation Fifteen, a nonprofit organization dedicated to supporting mental health and suicide prevention, is launching a new lifesaving campaign aimed at providing mental health resources to at-risk youth in the Noel, Missouri, area. The campaign is named in memory of Landen Russell Cates, who tragically passed away at the age of 15. His story highlights the urgent need for accessible mental health support for young people, especially those struggling in silence.
The “Landen’s Legacy: Youth Mental Health Support Initiative” aims to tackle the mental health crisis by offering financial assistance for therapy, peer mentorship programs, and educational workshops focused on suicide prevention and awareness. The initiative will target teens facing mental health challenges, providing them with resources and support to help them thrive emotionally and psychologically.
The campaign will work closely with local schools, community centers, and healthcare professionals to ensure that the mental health needs of vulnerable youth in the area are met. By addressing the stigma surrounding mental health and providing direct access to therapy and community-based support, Foundation Fifteen hopes to create a lasting change in how youth mental health is handled in Missouri.
A spokesperson for Foundation Fifteen explained, “Our mission is to break down the barriers that prevent young people from seeking help. Too many teens feel isolated and unsure about where to turn when they’re struggling. Through this campaign, we’re making sure that mental health support is not only available but also accessible and normalized within our community.”
The campaign will include a series of outreach events, awareness programs, and fundraising initiatives designed to both educate and raise funds for mental health services in the region. In addition to providing financial assistance for therapy, the program will also offer a range of workshops on emotional resilience, stress management, and self-care practices aimed at empowering teens to manage their mental well-being.
Foundation Fifteen’s new campaign comes at a critical time, as more young people are facing heightened levels of anxiety, depression, and isolation in the wake of the ongoing pandemic. With the increase in mental health struggles among teens, initiatives like these are more vital than ever to ensure that youth receive the care they deserve before reaching a crisis point.
“We’ve seen the effects of untreated mental health issues, and it’s heartbreaking to think about how many teens feel like they have nowhere to turn,” the spokesperson continued. “Our goal is to provide a safe space for young people to seek support and to empower families with the tools they need to address their children’s mental health needs effectively.”
The campaign is set to run throughout the year, with the hope that it will create long-term change by fostering a more open, supportive environment for teens facing mental health challenges. Foundation Fifteen is encouraging community members to get involved by donating, volunteering, and spreading the word about the importance of mental health in today’s youth.
About Foundation Fifteen
Foundation Fifteen is a nonprofit organization committed to supporting mental health awareness and suicide prevention and providing resources for at-risk youth. Founded in memory of Landen Russell Cates, the organization aims to empower young people with the tools they need to overcome mental health challenges. Foundation Fifteen offers a variety of services, including peer mentorship, therapy assistance, and educational outreach, to ensure that every teen has access to the support they need to thrive emotionally. Their mission is to break down mental health stigma and create a community where every young person feels valued and heard.
Contact Information
Website: https://foundationfifteen.org
Address: 93 Colony Drive, Noel, MO 64854, McDonald
Email Address: contact@foundationfifteen.org
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
SHENZHEN, CHINA – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.
The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.
According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.
“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum
At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.
To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.
Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.
Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.
CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.
Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth
According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.
Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.
In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.
Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source: China Medical System Holdings Ltd.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Crown Point Capital Releases Mid-Year Performance Overview Reinforcing Investor Confidence
Crown Point Capital has released its mid-year performance overview for 2025, highlighting steady growth, robust client engagement, and a strengthened market position. The report reflects the company’s ongoing ability to deliver consistent results across varying market conditions, reinforcing confidence among its expanding global investor base.
Strong Performance in a Volatile Market
The first half of 2025 has been marked by uncertainty across global financial markets. Digital assets in particular have experienced significant volatility, testing the resilience of platforms and investors alike. Despite these conditions, Crown Point Capital has demonstrated stability, maintaining steady growth and reinforcing its position as a secure trading platform for clients worldwide.
The firm’s strategies have been focused on balancing innovation with responsibility, ensuring that investor portfolios are supported with effective risk management frameworks. This approach has been recognized in Crown Point Capital reviews, where clients frequently note the platform’s ability to remain reliable even during turbulent market cycles.
Delivering Consistency for Clients
Crown Point Capital’s mid-year results confirm that consistency remains a defining feature of its operations. By prioritizing stability alongside growth, the company has delivered results that underscore its long-term focus on client success.
The performance overview also reflects the impact of the firm’s investments in technology and infrastructure. These enhancements have supported trading efficiency, safeguarded client assets, and improved overall platform reliability. Positive sentiment in Crown Point Capital reviews often highlights these qualities as key reasons for investor confidence in the company.
Expanding Global Reach
A significant theme in the mid-year report is Crown Point Capital’s expanding global reach. The company has broadened access to its platform across multiple regions, responding to growing international demand for digital asset trading solutions.
This global expansion has been supported by scalable infrastructure and adaptive strategies, ensuring the platform can meet the needs of both retail and institutional clients. The breadth of this reach has contributed to the company’s reputation as a forward-looking trading platform, a reputation frequently reflected in Crown Point Capital reviews.
Focus on Investor Protection
The mid-year overview also highlighted Crown Point Capital’s continued emphasis on investor protection. In an industry where transparency and security are increasingly valued, the company has reinforced its protective measures, introduced additional oversight processes, and strengthened reporting standards.
These initiatives are designed to provide investors with clarity and confidence, particularly during periods of market uncertainty. By embedding protection into every stage of its operations, Crown Point Capital is ensuring that growth opportunities are balanced with safeguards. This balance is frequently cited in Crown Point Capital reviews, where clients describe the firm as both innovative and dependable.
Strategic Adaptability
Adaptability has been another defining feature of Crown Point Capital’s performance in 2025. The company has demonstrated its ability to respond quickly to shifting market conditions, adjusting its strategies to ensure both resilience and opportunity.
This flexibility has been crucial in delivering positive outcomes despite unpredictable market movements. By refining its approach in real time, the firm has shown that it can remain competitive while protecting client interests. Such adaptability continues to strengthen investor confidence, a sentiment often echoed in Crown Point Capital reviews.
Building for the Future
Looking ahead, Crown Point Capital has indicated that it will continue to build on the progress achieved during the first half of the year. The company’s roadmap includes further enhancements to its trading infrastructure, expanded investor support programs, and additional initiatives aimed at strengthening transparency and long-term trust.
By maintaining a focus on innovation, accountability, and client protection, Crown Point Capital is positioning itself to sustain growth through the remainder of 2025 and beyond. The mid-year performance overview demonstrates not only past achievements but also a clear vision for the future, aligning the company with the expectations of global investors.
Conclusion
The release of Crown Point Capital’s mid-year performance overview underscores the company’s resilience, adaptability, and commitment to clients in an evolving market. By delivering consistent results, reinforcing transparency, and expanding global access, the firm continues to strengthen investor confidence and set a benchmark for responsible trading platforms.
As the financial landscape continues to change, Crown Point Capital remains focused on its mission to combine innovation with security, providing investors with a reliable foundation for long-term growth.
Media Contact
Organization: Crown Point Capital
Contact Person: david adler
Website: https://www.crownpoint-capital.com
Email: Send Email
Address:10 St. Petersrasse
City: Zurich
State: Zurich
Country:Switzerland
Release id:32584
The post Crown Point Capital Releases Mid-Year Performance Overview Reinforcing Investor Confidence appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
SHENZHEN, CHINA – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.
The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.
According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.
“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum
At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.
To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.
Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.
Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.
CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.
Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth
According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.
Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.
In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.
Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source: China Medical System Holdings Ltd.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
Crown Point Capital Releases Mid-Year Performance Overview Reinforcing Investor Confidence
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
Microsoft License Enables Organizations to Navigate the Evolving Digital Landscape Through Customized Microsoft Solutions
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
-
Press Release6 days ago
2025’s Top 6 Free Cloud Mining Platforms Revealed: XRP Community Sparks Discussion on Stable Earning Strategies
-
Press Release3 days ago
Sunrise Pact Investment Alliance Integrates Alaric Wainwright’s NeuroGrid AI Into Global Fintech Rollout
-
Press Release7 days ago
MH Markets Announces a Phased Strategic Investment in FCA-Regulated Asset Management Firm, Further Strengthening Global Compliance and Institutional Service Capabilities
-
Press Release1 week ago
From XRP to BTC: How Find Mining’s Cloud Plan Creates Steady Passive Returns
-
Press Release4 days ago
Instant Mobile Mining: OPTO Miner App Lets Users Earn Passive Income in XRP and BTC
-
Press Release1 week ago
Sebastian Najera Latin YouTube Mentor Launches New Era of Faceless Content with Explosive Student Growth
-
Press Release1 week ago
Ripplecoin Mining Debuts Cloud Mining App Amid Ethereum’s Bull Run
-
Press Release4 days ago
CT Crypto Financial Limited Expands Global Digital Asset Operations with Innovative Web3 Strategy